Back to Cancer Australia's website

Cancer Australia

Select a guideline

Recommendations for use of Chemotherapy

References

  1. National Breast Cancer Centre. Clinical practice guidelines for the management of advanced breast cancer. Canberra: Commonwealth of Australia; 2001.
  2. National Breast and Ovarian Cancer Centre. Recommendations for use of endocrine therapy for the treatment of hormone receptor-positive advanced breast cancer. Surry Hills: National Breast and Ovarian Cancer Centre; 2008.
  3. National Breast Cancer Centre. Recommendations for use of trastuzumab (Herceptin ) for the treatment of HER2-positive breast cancer. Camperdown: National Breast Cancer Centre; 2007.
  4. Wilcken N, Dear R. Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007. Eur J Cancer 2008;44:2218-25.
  5. Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews (Online) 2005:CD003372.
  6. University of South Australia Sansom Institute. Comparison of taxane containing regimens for metastic breast cancer. Adelaide: University of South Australia Sansom Institute; 2008.*
  7. University of South Australia Sansom Institute. Addition of targeted therapies (bevacizumab and lapatinib) to a chemotherapy regimen for metastatic breast cancer. Adelaide: University of South Australia Sansom Institute; 2008.*
  8. National Breast Cancer Centre and National Cancer Control Initiative. Clinical practice guidelines for the psychosocial care of adults with cancer. Camperdown: National Breast Cancer Centre; 2003.
  9. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. In. Canberra: Commonwealth of Australia; 2001.
  10. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003;21:588-92.
  11. Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006;24(18S):Abstract 570.
  12. Gennari A, Sormani M, Bruzzi P, et al. A meta-analysis of chemotherapy duration in metastatic breast cancer (MBC). 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2008;26(15S):Abstract 1067.
  13. Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-6.
  14. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9.
  15. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004;22:2061-8.
  16. Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006;24:4963-70.
  17. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
  18. Guan Z, Feng F, Li QL, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S):Abstract 1038.
  19. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-9.
  20. Stockler M, Sourjina T, Grimison P, et al. A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007;25(18S):Abstract 1031.
  21. O Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-23.
  22. Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950-7.
  23. Zon R, Miller K, Wang M, et al. A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100. European Journal of Cancer Supplements 2006;4.
  24. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Journal of Clinical Oncology 2008;26(15S):LBA1011.
  25. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
  26. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
  27. Geyer CE, Martin A, Newstat B, et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18S):Abstract 1035.
  28. O Shaughnessy J, Osborne C, Pippen J, et al. Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC). In: San Antonio Breast Cancer Symposium. Texas USA; 2009:Abstract 3122.
  29. Robert N, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(15s):Abstract 1005.
  30. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
  31. Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005;16:899-908.
  32. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-15.
  33. Bontenbal M, Creemers GJ, Braun HJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005;23:7081-8.
  34. Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23:5542-51.
  35. Icli F, Akbulut H, Uner A, et al. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer 2005;92:639-44.
  36. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-5.
  37. Tannock IF, Boyd NF, DeBoer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988;6:1377-87.
  38. Farquhar C, Marjoribanks J, Basser R, Hetrick S, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane database of systematic reviews (Online) 2005:CD003142.
  39. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
  40. Wagner LI, Wang M, Miller K, et al. Health-related quality of life among patients with metastic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the eastern cooperative oncology group (ECOG) study E2100. Breast Cancer Treatment and Research 2006;100(Supplement 1):Abstract 5078.

* Available on request from NBOCC

Related Links

Published using CeCC Docbook Manager